| A096 |
STX-100 Biosimilar(Anti-Integrin aVb6 (ITGAV & ITGB6) Reference Antibody)
Featured
|
|
|
| A097 |
Abrilumab Biosimilar(Anti-Integrin a4b7 (ITGA4 & ITGB7) Reference Antibody)
Featured
|
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD). |
.png)
|
| A098 |
Batoclimab Biosimilar(Anti-FcRn (FCGRT & B2M) Reference Antibody)
Featured
|
Batoclimab is a human anti-FcRn monoclonal antibody. Batoclimab can be used for the research of autoimmune diseases mediated by pathogenic IgG antibodies. |
.png)
|
| A099 |
1A6 Biosimilar(Anti-FGF19 Reference Antibody)
Featured
|
|
|
| A100 |
HuGAL-F2 Biosimilar(Anti-FGF2 Reference Antibody)
Featured
|
|
|
| A101 |
Burosumab Biosimilar(Anti-FGF23 Reference Antibody)
Featured
|
Burosumab is a human fibroblast growth factor 23 (FGF23) neutralizing antibody that can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia. |
.png)
|
| A102 |
Lilly patent anti-FGFR-1 Biosimilar(Anti-FGFR1 / CD331 Reference Antibody)
Featured
|
|
|
| A103 |
Aprutumab Biosimilar(Anti-FGFR2 / CD332 Reference Antibody)
Featured
|
Aprutumab (BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research. |
.png)
|
| A104 |
Bemarituzumab Biosimilar(Anti-FGFR2 / CD332 Reference Antibody)
Featured
|
Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research. |
.png)
|
| A105 |
Vofatamab Biosimilar(Anti-FGFR3 / CD333 Reference Antibody )
Featured
|
Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). |
.png)
|
| A106 |
U3-1784 Biosimilar(Anti-FGFR4 / CD334 Reference Antibody)
Featured
|
|
|
| A107 |
Radretumab Biosimilar(Anti-Fibronectin Reference Antibody)
Featured
|
|
.png)
|
| DC66691 |
L19TNF
Featured
|
|
|
| A109 |
Rosopatamab Biosimilar(Anti-FOLH1 / PSMA Reference Antibody)
Featured
|
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 (177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency. |
.png)
|
| A110 |
Pelgifatamab Biosimilar(Anti-FOLH1 / PSMA Reference Antibody)
Featured
|
Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody. Pelgifatamab can be covalently linked to a binding moiety of 225Ac and used for metastatic castration-resistant prostate cancer (mCRPC) research. |
.png)
|
| A111 |
Mirvetuximab Biosimilar(Anti-FOLR1 / FRA Reference Antibody)
Featured
|
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research. |
.png)
|
| DC66695 |
Cofrogliptin
Featured
|
Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) . |
|
| DC66696 |
(R)-2-Thioxothiazolidine-4-carboxylic acid-13C3
Featured
|
(R)-2-Thioxothiazolidine-4-carboxylic acid-13C3 is the 13C-labeled (R)-2-Thioxothiazolidine-4-carboxylic acid. Radioactive isotopes labeled compounds can be used in metabolic analysis, allowing the movement of individual atoms to be precisely tracked and quantified. |
|
| DC66697 |
2-Thioxothiazolidine-4-carboxylic Acid
Featured
|
|
|
| DC66698 |
STING agonist-12
Featured
|
STING agonist-12 (Compound 53) is a potent, orally active human STING activator with an EC50 of 185 nM. |
|
| A619 |
Sacituzumab govitecan
Featured
|
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity. |
|
| DC66700 |
(S,R)-LSN3318839
Featured
|
(S,R)-LSN3318839 is the stereoisomer of LSN3318839 (HY-142162). LSN3318839 is an orally active positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R). |
|
| DC66701 |
(3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)pyrrolidin-3-ol
Featured
|
|
|
| A112 |
Farletuzumab Biosimilar(Anti-FOLR1 / FRA Reference Antibody)
Featured
|
Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer. |
.png)
|
| A114 |
Dompe patent anti-FOLR1 Biosimilar(Anti-FOLR1 / FRA Reference Antibody)
Featured
|
|
|
| A116 |
BMS-986012 Biosimilar（Anti-Fucosyl GM1 Reference Antibody）
Featured
|
|
|
| A130 |
Vantictumab Biosimilar（Anti-FZD Reference Antibody）
Featured
|
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma. |
.png)
|
| A131 |
U.Toronto patent anti-FZD7 Biosimilar（Anti-FZD7 Reference Antibody）
Featured
|
|
|
| DC60641 |
CD-005
Featured
|
CD-005 is a low-molecular-weight gelator that can be used to prepare gels for proteins and vaccines. CD-005 can physically entrap proteins, preventing their irreversible aggregation, and maintain protein function for at least 4 weeks even at temperatures up to 50°C. |
|
| DC66707 |
Casdatifan
Featured
|
Casdatifanum is a hypoxia-inducible factor (HIF) inhibitor. |
|
